Switzerland-based Novartis has received a US Food and Drug Administration (FDA) priority review for its gene therapy Zolgensma (onasemnogene abeparvovec-xxxx), which was formerly known as AVXS-101, intended for the treatment of spinal muscular atrophy Type 1, it was reported on Tuesday.
Zolgensma was earlier granted breakthrough therapy designation by the US regulator. The product, which is intended to be delivered as a single, one-time infusion, functions by replacing the missing or defective SMN1 gene with a functional copy that makes SMN protein. Through this mechanism, the gene therapy is said to help in improving motor neuron function and survival.
The company expects a regulatory action to be taken on the gene replacement therapy in May 2019. The investigational gene therapy was originally developed by AveXis, a US-based clinical stage gene therapy company that Novartis purchased for USD8.7bn in an all-cash deal this year.
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain